Drugs / GS-9901
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02258555 | Jan → Aug 2015 | chronic lymphocytic leukemia/small lymphocytic lymphoma, follicular lymphoma, marginal zone lymphoma | Gilead Sciences | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GS-9901 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02258555 ↗ |
| Modality | Small molecule | — CHEMBL3928407 ↗ |
| Route | Oral | “administered orally” NCT02258555 ↗ |